Competitors ahead of us have failed with the TSS and that's what the FDA hold in the highest regard.
Safety profile paramount in this patient population. You can see why Hashan thinks in the long run, SNT-5505 could potentially be part of the standard of care in the early patient population = big $$$
- Forums
- ASX - By Stock
- Ann: Presentation: Phase 2 study of SNT-5505 in myelofibrosis
SNT
syntara limited
Add to My Watchlist
1.72%
!
5.7¢

Competitors ahead of us have failed with the TSS and that's what...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
5.7¢ |
Change
-0.001(1.72%) |
Mkt cap ! $92.62M |
Open | High | Low | Value | Volume |
5.8¢ | 5.9¢ | 5.6¢ | $174.0K | 3.073M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 83031 | 5.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.7¢ | 483082 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 83031 | 0.055 |
2 | 110908 | 0.054 |
4 | 394430 | 0.053 |
3 | 172230 | 0.052 |
3 | 372100 | 0.051 |
Price($) | Vol. | No. |
---|---|---|
0.057 | 483082 | 1 |
0.060 | 240854 | 3 |
0.061 | 150000 | 1 |
0.062 | 125000 | 3 |
0.063 | 568340 | 2 |
Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
Featured News
SNT (ASX) Chart |
The Watchlist
CDE
CODEIFAI LIMITED
John Houston / Martin Ross, Executive Chairman / COO
John Houston / Martin Ross
Executive Chairman / COO
Previous Video
Next Video
SPONSORED BY The Market Online